BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30606702)

  • 1. The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis.
    Cargo C; Cullen M; Taylor J; Short M; Glover P; Van Hoppe S; Smith A; Evans P; Crouch S
    Blood; 2019 Mar; 133(12):1325-1334. PubMed ID: 30606702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
    Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
    Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of immunophenotypic analysis in distinguishing chronic myelomonocytic leukemia from reactive monocytosis.
    Feng R; Bhatt VR; Fu K; Pirruccello S; Yuan J
    Cytometry B Clin Cytom; 2018 Nov; 94(6):901-909. PubMed ID: 30334354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
    Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
    Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis.
    Xu Y; McKenna RW; Karandikar NJ; Pildain AJ; Kroft SH
    Am J Clin Pathol; 2005 Nov; 124(5):799-806. PubMed ID: 16203279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-related mutations and chronic myelomonocytic leukemia.
    Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
    Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
    Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
    Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime?
    Solary E; Wagner-Ballon O; Selimoglu-Buet D
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101134. PubMed ID: 32460985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
    Calvo X; Garcia-Gisbert N; Parraga I; Gibert J; Florensa L; Andrade-Campos M; Merchan B; Garcia-Avila S; Montesdeoca S; Fernández-Rodríguez C; Salido M; Puiggros A; Espinet B; Colomo L; Roman-Bravo D; Bellosillo B; Ferrer A; Arenillas L
    Blood Adv; 2020 Oct; 4(20):5285-5296. PubMed ID: 33108455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
    Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
    Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyte subsets to differentiate chronic myelomonocytic leukemia from reactive monocytosis.
    Hwang SM; Ahn H; Jeon S; Park J; Chang Y; Kim H
    J Clin Lab Anal; 2021 Jan; 35(1):e23576. PubMed ID: 32931067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
    Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
    Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations.
    Franzini A; Pomicter AD; Yan D; Khorashad JS; Tantravahi SK; Than H; Ahmann JM; O'Hare T; Deininger MW
    Blood Adv; 2019 Oct; 3(20):2949-2961. PubMed ID: 31648319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia.
    Moon Y; Kim MH; Kim HR; Ahn JY; Huh J; Huh JY; Han JH; Park JS; Cho SR
    Ann Lab Med; 2018 Sep; 38(5):481-483. PubMed ID: 29797820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
    Elena C; Gallì A; Such E; Meggendorfer M; Germing U; Rizzo E; Cervera J; Molteni E; Fasan A; Schuler E; Ambaglio I; Lopez-Pavia M; Zibellini S; Kuendgen A; Travaglino E; Sancho-Tello R; Catricalà S; Vicente AI; Haferlach T; Haferlach C; Sanz GF; Malcovati L; Cazzola M
    Blood; 2016 Sep; 128(10):1408-17. PubMed ID: 27385790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
    Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
    J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
    Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
    Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
    Ouyang Y; Qiao C; Chen Y; Zhang SJ
    Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
    Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.